The growing demand for natural compounds in food, pharmaceuticals, and agriculture has placed immense pressure on traditional extraction methods from plants. Among these compounds, thymol and carvacrol—naturally occurring phenolic monoterpenes—stand out for their powerful antimicrobial, antioxidant, anti-inflammatory, and anticancer properties. Traditionally sourced from thyme (Thymus vulgaris) and other Lamiaceae plants, large-scale production has been costly and resource-intensive.
Now, a team of researchers has successfully engineered the oleaginous yeast Yarrowia lipolytica to act as a microbial cell factory, enabling the sustainable, de novo biosynthesis of thymol and carvacrol for the first time.
Why Thymol and Carvacrol Matter
These bioactive molecules are widely used as:
- Food preservatives & antioxidants
- Pharmaceutical agents with antimicrobial and anticancer potential
- Eco-friendly agricultural protectants against plant diseases
With increasing interest in natural and sustainable alternatives to synthetic chemicals, scaling up their production through biotechnology represents a game-changing opportunity.
The Yeast Engineering Breakthrough
The study constructed a complete synthetic pathway of thymol and carvacrol in Yarrowia lipolytica. By strategically enhancing metabolic flux and gene expression, the team achieved:
- An 18.44-fold increase in production by optimizing the mevalonate (MVA) pathway.
- A 1.75-fold boost by increasing copy numbers of key plant-derived genes (TvCYP71D507 + TvTPS2 + TvSDR1).
- A final engineered strain (CT18) that reached titers of 7.14 mg/L in shake flasks and an impressive 61.31 mg/L in a 5-L bioreactorEngineering the oleaginous yeas….
This is the first successful demonstration of de novo thymol and carvacrol biosynthesis in yeast, paving the way for scalable, eco-friendly production.
Applications and Future Potential
By shifting production from plant extraction and chemical synthesis to microbial fermentation, this approach:
- Reduces environmental impact
- Lowers production costs
- Enables industrial scalability
- Opens doors to derivative compounds like thymoquinone, which has higher pharmaceutical value
Future improvements may include protein engineering, adaptive evolution, and compartmentalization strategies to push yields even higher.
Conclusion
The engineering of Yarrowia lipolytica for thymol and carvacrol production marks a milestone in synthetic biology and metabolic engineering. This innovation not only ensures a sustainable supply of valuable phenolic monoterpenes but also establishes yeast as a versatile microbial platform for producing plant-derived bioactive compounds at scale.
As industries move toward greener and safer alternatives, microbial production of thymol and carvacrol could reshape pharmaceuticals, food safety, and agriculture worldwide.
Reference
Zhu, J., Zhang, Y., Jiang, H., Zheng, M., & Gong, Y. (2025). Engineering the oleaginous yeast Yarrowia lipolytica for co-production of phenolic monoterpenes thymol and carvacrol. Microbial Cell Factories, 24(1), 208. https://doi.org/10.1186/s12934-025-02836-4
Related posts:
Revolutionizing TUDCA Production: How Engineered Bacillus subtilis Unlocks a Cost-Effective Bear Bile Alternative
Revolutionizing L-Lactic Acid Production: How Engineered E. coli Transforms Sucrose into Sustainable Biochemicals
New Class of Antibiotics with a Novel Mode of Inhibition against World Health Organization’s Critical Listed Bacteria, Carbapenem-Resistant Acinetobacter baumannii
Revolutionizing Water Safety: Multichannel Bioelectronic Sensors with Engineered E. coli
Planting Nitrogen-Fixing Species Can Boost Soil Carbon and Fight Climate Change
